Download a complete bibliography from each of our ongoing investigational programs below.
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of SPR994 for multidrug resistant Enterobacteriaceae
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multidrug resistant Enterobacteriaceae in a hollow fibre infection model
Tebipenem HBR
Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with varying degrees of renal impairment
Tebipenem HBR
Oral tebipenem pivoxil is non-inferior to IV ertapenem in complicated urinary tract infection and acute pyelonephritis: ADAPT-PO Study
SPR720
Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02469-20.
Tebipenem HBR
Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.
Tebipenem HBR
Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 2022;386:1327-38.
Tebipenem HBR
Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro infection model
Tebipenem HBR
Molecular epidemiology of Escherichia coli causing urinary tract infections in United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018–2020)
SPR206
SPR206: Next generation polymyxin for the treatment of highly resistant gram-negative bacterial infections
SPR206
Optimization of next-generation polymyxins leading to SPR206 as a development candidate
Tebipenem HBR
Monitoring the in vitro activity of tebipenem, an orally available carbapenem agent, against a current collection of surveillance Enterobacteriaceae clinical isolates (2018)
Tebipenem HBR
Medicare spending on urinary tract infections: a retrospective database analysis
SPR741
Mendes RE, Rhomberg PR, Lister T, et al. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Microb Drug Resist. 2020 Apr;26(4):319-328.
SPR741
Mendes RE, Rhomberg PR, Lister T, et al. In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae, Including Molecularly Characterized Strains. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00742-20.
Tebipenem HBR
McEntee L, Johnson A, Farrington N, et al. Pharmacodynamics of tebipenem: New options for oral treatment of multidrug-resistant gram-negative infections. Antimicrob Agents Chemother. 2019 Jul 25;63(8): e00603-19.
SPR206
Mechanism of action of SPR206, a next-generation polymyxin active against gram-negative pathogens
Tebipenem HBR
Lodise TP, Chopra T, Nathanson BH, Sulham K. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021 May 30:S0196-6553(21)00382-5.
Tebipenem HBR
Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.
Tebipenem HBR
Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522.
Tebipenem HBR
Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals
Tebipenem HBR
Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis
Tebipenem HBR
Lacasse E, Brouillette E, Larose A, et al. In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
SPR720
Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01503-18.
SPR206
Brown P, Abdulle O, Boakes S, et al. Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin. ACS Infect Dis. 2021 Apr 9;7(4):894-905.
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection
SPR206
In vivo efficacy of SPR206 in murine lung and thigh infection models caused by multi-drug resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii
SPR206
In vivo efficacy of SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli
Tebipenem HBR
In vitro minimum inhibitory and minimum bactericidal concentrations of tebipenem and comparators against contemporary Enterobacterales tested in pooled human urine at varied pH
SPR206
In vivo efficacy of next-generation polymyxin SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli
SPR720
In vitro characterization of a novel gyrase inhibitor (SPR719) against nontuberculous Mycobacteria
Tebipenem HBR
In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract model
SPR206
In vitro bactericidal activity of next-generation polymyxin SPR206 against susceptible and multidrug-resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae as compared to levofloxacin and meropenem
Tebipenem HBR
In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM)
Tebipenem HBR
In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa
Tebipenem HBR
In vitro activity of tebipenem (SPR859), tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria
Tebipenem HBR
In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative bacteria
Tebipenem HBR
In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program
Tebipenem HBR
In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance gram-positive clinical isolates
Tebipenem HBR
In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera
Tebipenem HBR
In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
Tebipenem HBR
Hospital costs and reimbursement in patients with resistant Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis
Tebipenem HBR
Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera - pipeline drugs to treat
SPR206
In vitro activity evaluation of a next-generation polymyxin, SPR206, against non-fermentative gram-negative bacilli responsible for human infections
SPR741
In vitro activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria
Tebipenem HBR
Impact of varied test conditions on the in vitro activity of tebipenem (SPR859) and meropenem against urinary pathogens, including those expressing extended-spectrum beta-lactamases (ESBL)
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
